Clinical trials: Amnesia
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Memory Disorders, Postmenopausal Symptoms
The Effect of a Multivitamin in the Treatment of Memory Loss in Postmenopausal Women
Complaints about memory loss are very common in women in the menopausal transition period. The effectiveness of estrogen replacement therapy in cognitive improvement is controversial.
- Trial name
- NCT03835325
- Testing
- Cogmax®
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Early Memory Loss, Mild Cognitive Impairment
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®.
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Trial name
- NCT01370954
- Testing
- CerefolinNAC®
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.